**Background**
Bacterial infections caused by drug-resistant pathogens remain a critical challenge in modern medicine. Pathogens such as Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae often exhibit resistance to conventional antimicrobial therapies, leading to increased morbidity and mortality in patients with severe respiratory and systemic infections. The development of potent, broad-spectrum antibiotics capable of overcoming these resistance mechanisms is essential for improving clinical outcomes. Fluoroquinolones are a well-established class of antibiotics that target bacterial DNA gyrase and topoisomerase IV to inhibit DNA replication. In this context, we will introduce a broad-spectrum fluoroquinolone antibiotic – Delafloxacin.
**Definition**
Delafloxacin is a broad-spectrum fluoroquinolone antibiotic that targets the quinolone binding site to inhibit bacterial growth. According to the Delafloxacin description, it exhibits potent activity against a wide range of Gram-positive and Gram-negative bacteria, including drug-resistant strains.
**In Vitro and In Vivo Studies**
The Delafloxacin biological activity has been extensively evaluated across various bacterial strains. In vitro studies demonstrated that Delafloxacin effectively inhibited S. aureus strains ATCC 29213, ATCC 33591, MW2, and R2527 with MICs of 0.008, 0.008, 0.004, and 0.004 mg/L, respectively. It also inhibited S. pneumoniae strains ATCC 10813, ATCC 49619, 145, and 1329 with MICs ranging from 0.016 to 0.125 mg/L, and K. pneumoniae strains ATCC 43816, 4105, 4110, and 81-1260A with MICs between 0.06 and 1 mg/L.
Regarding Delafloxacin in vivo performance, research utilizing a neutropenic murine lung infection model showed that subcutaneous injections (total daily doses from 0.156 to 640 mg/kg/24 h) were highly effective against S. aureus. Even at the lowest doses, a decrease of 1.5 to 2.2 log10 CFU in organism burden was observed compared to untreated controls, with net bactericidal activity noted for strains MW2 and R2527. At maximal doses, a >4-log10 kill from the initial burden was achieved for all S. aureus strains. Pharmacokinetic analysis in neutropenic mice (2.5, 10, 40, and 160 mg/kg; subcutaneous injection) revealed that maximum drug concentrations (Cmax) ranged from 2 to 71 mg/L, with AUC 0-∞ values between 2.8 and 152 mg•h/L. The elimination half-life (t1/2) was found to be moderate, ranging from 0.7 to 1 h. In conclusion, Delafloxacin is a potent broad-spectrum antibiotic with significant efficacy against drug-resistant respiratory pathogens.
Keywords
Delafloxacin, 189279-58-1, RX-3341, WQ-3034, ABT492, RX3341, RX 3341, WQ3034, WQ 3034, ABT 492, ABT-492, Bacterial, Antibiotic
References